With 0.67 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.19 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.4531 whereas the lowest price it dropped to was $7.265. The 52-week range on JBIO shows that it touched its highest point at $92.46 and its lowest point at $4.57 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 0.79.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of JBIO was up-trending over the past week, with a rise of 7.08%, but this was down by -14.33% over a month. Three-month performance dropped to -14.98% while six-month performance fell -17.32%. The stock lost -88.84% in the past year, while it has lost -20.44% so far this year. A look at the trailing 12-month EPS for JBIO yields -59.44 with Next year EPS estimates of -15.66. For the next quarter, that number is -3.15. This implies an EPS growth rate of 81.58% for this year and -18.90% for next year. EPS is expected to grow by 67.92% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -77.98%.
Float and Shares Shorts:
At present, 0.83 million JBIO shares are outstanding with a float of 0.60 million shares on hand for trading. In addition to Mr. Tom Frohlich as the firm’s CEO & Director, Mr. Jonathan Quick serves as its Senior Vice President of Finance.
Institutional Ownership:
Through their ownership of 0.30898002 of JBIO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, JBIO reported revenue of $0.0 and operating income of -$15555000.0.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With JBIO analysts setting a high price target of 19.0 and a low target of 17.0, the average target price over the next 12 months is 18.0. Based on these targets, JBIO could surge 146.43% to reach the target high and rise by 120.49% to reach the target low. Reaching the average price target will result in a growth of 133.46% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
